• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$7.35 $0.03 (0.41%)

REAL-TIME: Last trade at

ACHILLION PHARMACEUTICALS, INC...

NASDAQ:ACHN

Jump to this page for:

Related Resources

Too Little, Too Late for Achillion?

5/22/2012 by DailyFinance

5 of Last Week's Biggest Winners

5/14/2012 by DailyFinance

Is Vertex Pharmaceuticals the Perfect Stock?

5/8/2012 by DailyFinance

Will Gilead Sciences Help You Retire Rich?

5/3/2012 by DailyFinance

Why Did The Market Trip These Stocks Up?

4/24/2012 by DailyFinance

A Bad News Buy for Gutsy, Patient Investors

4/24/2012 by DailyFinance

Achillion Shares Slide On Results From Hepatitis C Study

4/23/2012 by Smart Money

Why Achillion Pharmaceuticals Tanked

4/23/2012 by DailyFinance

Gilead, Bristol Shine at EASL Conference

4/21/2012 by DailyFinance

Hepatitis C drug stocks back in play

4/19/2012 by MarketWatch

Why the Hepatitis C Sector Popped and Dropped

4/19/2012 by DailyFinance

2nd UPDATE: Gilead, Bristol's Hepatitis C Drugs Show Promise In Study

4/19/2012 by Smart Money

Top Analyst Upgrades & Downgrades (ACHN, AAPL, BSX, CLS, C, CTRN, FSLR, HAIN, IDIX, INFY, NCT, SAP,

4/17/2012 by 247wallst

24/7 Wall St. Closing Bell (AAPL, ARMH, QCOM, ZNGA, HALO, CWTR, FTK, HOTT, KFY, AONE, ACHN, FSYS, JK

3/8/2012 by 247wallst

3 Signs of a Hepatitis C Bubble

2/29/2012 by DailyFinance

Don't Count Vertex Out Just Yet

2/28/2012 by DailyFinance

Gilead Sciences Shares Dropped: What You Need to Know

2/17/2012 by DailyFinance

2nd UPDATE: Patients On Gilead's Hepatitis C Drug Relapse In Trial

2/17/2012 by Smart Money

Has Gilead Sciences Become the Perfect Stock?

1/30/2012 by DailyFinance

Company News for January 25, 2012 - Corporate Summary

1/25/2012 by Nasdaq

Biotech Investors Confident: Industry Sees Big VC Spending in 2011

1/25/2012 by DailyFinance

5 of Last Week's Biggest Losers

1/23/2012 by DailyFinance

The Week's Biggest Stock Laggards

1/22/2012 by DailyFinance

Optimism and Buyouts Keep Markets Humming

1/11/2012 by DailyFinance

Dance Ballmer, dance! Microsoft is back

1/9/2012 by CNN Money

US Stock Futures: HOT STOCKS TO WATCH

1/9/2012 by Smart Money

3 Reasons Hep C Premiums Might Not Last

1/9/2012 by DailyFinance

Hepatitis C Drug Developers Shares Soar After Bristol Deal

1/9/2012 by Smart Money

US Stock Futures: HOT STOCKS TO WATCH

1/4/2012 by Smart Money

Health Care's Hottest Duo

12/20/2011 by DailyFinance

Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies

12/5/2011 by DailyFinance

Inhibitex Soars as Investors Chase Hepatitis Drug Developers

11/29/2011 by Minyanville

The Biggest Fear for Hep C Investors

11/28/2011 by DailyFinance

Is Achillion Pharmaceuticals the Perfect Stock?

11/23/2011 by DailyFinance

Who's Next on Hep C Biotech Buyout Hit List?

11/22/2011 by DailyFinance

Pharmasset Acquired, Shares Jump 85%

11/21/2011 by DailyFinance

Top Ten Undervalued Stocks With Large Cash Cushions

11/21/2011 by Nasdaq

Top 10 Undervalued Stocks With Large Cash Cushions

11/18/2011 by DailyFinance

This Biotech Stock Rose for All the Wrong Reasons

11/18/2011 by DailyFinance

Biotech Update: Pharmasset’s Hepatitis C Drug Shows 100% Cure Rate in Ph2 Trial

11/9/2011 by Nasdaq
See More Articles...